Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Quantitative prediction of long-term molecular response in TKI-treated CML - Lessons from an imatinib versus dasatinib comparison.

Glauche I, Kuhn M, Baldow C, Schulze P, Rothe T, Liebscher H, Roy A, Wang X, Roeder I.

Sci Rep. 2018 Aug 17;8(1):12330. doi: 10.1038/s41598-018-29923-4.

2.

Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data.

Fassoni AC, Baldow C, Roeder I, Glauche I.

Haematologica. 2018 Nov;103(11):1825-1834. doi: 10.3324/haematol.2018.194522. Epub 2018 Jun 28.

3.

MAGPIE: Simplifying access and execution of computational models in the life sciences.

Baldow C, Salentin S, Schroeder M, Roeder I, Glauche I.

PLoS Comput Biol. 2017 Dec 15;13(12):e1005898. doi: 10.1371/journal.pcbi.1005898. eCollection 2017 Dec. Erratum in: PLoS Comput Biol. 2018 Mar 26;14 (3):e1006083.

4.

Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.

Proschmann R, Baldow C, Rothe T, Suttorp M, Thiede C, Tauer JT, Müller MC, Hochhaus A, Roeder I, Glauche I.

Haematologica. 2017 Feb;102(2):e39-e42. doi: 10.3324/haematol.2016.154138. Epub 2016 Nov 17. No abstract available.

5.

Model Based Analysis of Clonal Developments Allows for Early Detection of Monoclonal Conversion and Leukemia.

Baldow C, Thielecke L, Glauche I.

PLoS One. 2016 Oct 20;11(10):e0165129. doi: 10.1371/journal.pone.0165129. eCollection 2016.

6.

Drug target prioritization by perturbed gene expression and network information.

Isik Z, Baldow C, Cannistraci CV, Schroeder M.

Sci Rep. 2015 Nov 30;5:17417. doi: 10.1038/srep17417.

Supplemental Content

Loading ...
Support Center